Gerresheimer Successfully Finalises Formation of Joint Venture 'Kimble

Gerresheimer Successfully Finalises Formation of Joint Venture 'Kimble

July 10, 2007

    DUSSELDORF, Germany, July 4 /Xinhua-PRNewswire/ -- 

    -- Through the joint venture, Gerresheimer expands its
leading
       position in the field of life science research.

    -- CEO Dr. Axel Herberg: "The joint venture is an
important part of
       Gerresheimer's growth strategy and allows both
companies to
       profit from market and production synergies."

    -- Kimble Chase Life Science and Research Products LLC
had total
       sales of around EUR100 million in 2006 (pro forma).

    The formation of the joint venture was finalised
yesterday. On 20 March 2007 Gerresheimer had already
announced the establishment of the joint venture with a
subsidiary of Thermo Fisher Scientific Inc. (TMO) in the
USA. The outstanding conditions, particularly approval by
the antitrust authorities, have now been fulfilled.

    With a 51% share Gerresheimer has a majority interest
in the new company "Kimble Chase Life Science and
Research Products LLC" (Kimble Chase). TMO holds 49%
of the shares. The joint venture specialises in the
development, production and marketing of life science
products and employs around 1,500 people in seven
locations. Gerresheimer contributes production plants in
the USA, Mexico and China and TMO production plants in the
USA and Germany. The company is based in New Jersey/USA.
Its products are used in industrial pharmaceutical research
and are largely marketed under the trademarks Kimble, Kontes
and Bomex. In the financial year 2006, sales by Kimble Chase
totalled around EUR100 million (pro forma).

    "The joint venture marks another important step by
the Gerresheimer Group on the way to becoming a global
pharma & life science group. In this way we will
continue to pursue our growth strategy in the future and
offer our shareholders an attractive investment," says
Dr. Axel Herberg, CEO of Gerresheimer AG

    With Kimble Chase the Gerresheimer Group employs around
10,000 people in 37 locations around the world and
approaches a total sales level of EUR1 billion in 2007 as
planned. Since 11 June 2007 Gerresheimer has been listed in
the Prime Standard of the Frankfurt stock exchange,
following one of the largest flotations of the year with a
total issue volume of around EUR1 billion.

    Note to Editors

    You can request photos on this topic via our homepage. 
If required, we can also send you high-resolution data.
Reprint free of charge. Please send specimen copy to
Gerresheimer. 

    Gerresheimer is a pharmaceutical & life science
supply and services company with market leading positions
of specialty products made of glass and plastic.
Gerresheimer owns 37 production sites in Europe, North
America and Asia and employs approximately 10,000 employees
worldwide.



    For more information, please contact:

     Burkhard Lingenberg
     Director Corporate PR & Marketing
     Tel:   [phone]
     Email: [e-mail]